^
Association details:
Biomarker:KRAS mutation
Cancer:Colorectal Cancer
Drug:JZP815 (pan-RAF inhibitor, RAS inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

2677 / 20 - JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models

Published date:
03/09/2022
Excerpt:
JZP815 demonstrated enhanced activity when combined with inhibitors of other MAPK pathway components in both class 2 and class 3 mutant BRAF patient-derived tumor cells ex vivo, and KRAS mutant NSCLC and CRC xenografts in vivo.